Loading
A phase 3 trial testing HRS-8080 in HR-positive / HER2-negative breast cancer, now recruiting.
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy is a phase 3 interventional study registered as NCT07354022, led by Shandong Suncadia Medicine, and recruiting on the registry. Official title: A Multicenter, Open-label, Randomised Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HRS-8080 Combined With Dalpiciclib Versus Fulvestrant Combined With Dalpiciclib in Patients With Locally Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. Planned enrolment is 912 participants (estimated). The study started in 2026-05-05 and primary completion is expected in 2028-12. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals.
Shares Jiangsu Hengrui Pharmaceuticals, HR-positive / HER2-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/